Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)
- PMID: 15386719
- DOI: 10.1002/pds.936
Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)
Abstract
Purpose: To assess the safety of a licensed anthrax vaccine (AVA) given to more than 500,000 US military personnel, through review and medical evaluation of adverse events (AEs) reported to the Vaccine Adverse Event Reporting System (VAERS).
Methods: AEs were summarized by person, vaccine lot, type, frequency and impact. A Delphic approach was used to tentatively assess causality in an effort to detect serious AEs (SAEs) or other medically important AEs (OMIAEs) possibly attributable to AVA.
Results: The Anthrax Vaccine Expert Committee (AVEC) reviewed 1841 reports describing 3991 AEs (9.4 reports/10,000 doses of AVA) that were submitted to VAERS from 1Q1998 through 4Q2001. One hundred forty-seven reports described an SAE or OMIAE, of which 26 were tentatively rated as possible, probable or certain consequences of vaccination (injection-site reaction [12], 'anaphylactic-like reaction' [5] and eight other systemic AEs [1-2 each]).
Conclusions: This review produced no evidence for an unusual rate of any SAE or OMIAE attributable to AVA. It supported an earlier impression that AVA may cause significant local inflammation and should be administered over the deltoid rather than the triceps to avoid direct or compression injury to the ulnar nerve. The subjects of VAERS reports tended to be older than all recipients of AVA. Females generally had and/or reported AEs more often than males, but transient articular reactions were surprisingly more common in males. Variations in the frequency or severity (as judged by hospitalization and/or loss of duty) of reported AEs did not suggest a significant problem with (1) a particular lot of AVA, (2) recurrent AEs after multiple doses or (3) vaccination of persons with a concomitant illness or those given other vaccines or medications.
Copyright 2004 John Wiley & Sons, Ltd.
Similar articles
-
Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Pharmacoepidemiol Drug Saf. 2002 Apr-May;11(3):189-202. doi: 10.1002/pds.712. Pharmacoepidemiol Drug Saf. 2002. PMID: 12051118 Review.
-
Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.Vaccine. 2009 Jan 7;27(2):290-7. doi: 10.1016/j.vaccine.2008.10.044. Epub 2008 Nov 6. Vaccine. 2009. PMID: 18992783
-
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543
-
Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database.Hepatogastroenterology. 2004 May-Jun;51(57):762-7. Hepatogastroenterology. 2004. PMID: 15143911
-
Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.Vaccine. 2008 May 2;26(19):2428-32. doi: 10.1016/j.vaccine.2008.02.052. Epub 2008 Mar 17. Vaccine. 2008. PMID: 18406499 Review.
Cited by 16 articles
-
Analysis of Individual Differences in Vaccine Pharmacovigilance Using VAERS Data and MedDRA System Organ Classes: A Use Case Study With Trivalent Influenza Vaccine.Biomed Inform Insights. 2017 Apr 11;9:1178222617700627. doi: 10.1177/1178222617700627. eCollection 2017. Biomed Inform Insights. 2017. PMID: 28469434 Free PMC article.
-
Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease.Infect Immun. 2016 Nov 18;84(12):3408-3422. doi: 10.1128/IAI.00755-16. Print 2016 Dec. Infect Immun. 2016. PMID: 27647868 Free PMC article.
-
Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.Vaccine. 2016 Aug 17;34(37):4406-14. doi: 10.1016/j.vaccine.2016.07.019. Epub 2016 Jul 19. Vaccine. 2016. PMID: 27449076 Free PMC article.
-
Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination.Clin Vaccine Immunol. 2016 Aug 5;23(8):664-71. doi: 10.1128/CVI.00092-16. Print 2016 Aug. Clin Vaccine Immunol. 2016. PMID: 27280620 Free PMC article.
-
Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.Vaccine. 2014 Jun 12;32(28):3548-54. doi: 10.1016/j.vaccine.2014.04.025. Epub 2014 Apr 24. Vaccine. 2014. PMID: 24768633 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical